Related Experiment Video
Updated: Aug 16, 2026

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
The safety and tolerability of atypical antipsychotics in bipolar disorder
Florian Seemüller1, Anna Forsthoff, Sandra Dittmann
1Department of Psychiatry, Ludwigs-Maximilians-University, Nussbaumstr. 7, 80336 Munich, Germany.
Abstract:
Atypical antipsychotics (aAPs), have become a first-line treatment option, both in schizophrenia and bipolar disorders. Almost all aAPs now have proven efficacy in acute mania, some also in bipolar depression and in maintenance treatment. This provides reliable data on their safety and tolerability in this particular group of patients. This review focuses on the safety and tolerability of aAPs in the treatment of bipolar disorders. Both tolerability, for example, extrapyramidal symptoms, and safety issues, for example, occurrence of weight gain and hyperglycaemia, will be highlighted for olanzapine, quetiapine, risperidone, ziprasidone and aripiprazole.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Bipolar Disorder
Antipsychotic Drugs: Typical and Atypical Agents